2028, FDA Approval and Licensing - Drug Discovery Digest

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2028

FDA Approval

Licensing

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

The Pharma Data

JANUARY 9, 2021

. A follow-on procurement contract with HHS is expected for the delivery of raxibacumab, the Company’s Food and Drug Administration-approved anthrax monoclonal antibody therapeutic, to the Strategic National Stockpile (SNS). FOOTNOTES. (1)

Government

Government Vaccine Production Licensing

Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update

The Pharma Data

NOVEMBER 4, 2020

In addition, Amarin recognized licensing and royalty revenue of approximately $1.3 This compares with licensing and royalty revenue of $0.2 1 (908) 892-2028 PR@amarincorp.com (media inquiries). . Licensing and royalty revenue. million and $8.9 million and $5.7 million and $1.1 million and $346.5

Production

Production FDA Trials Licensing

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

Amarin Reports Third Quarter 2020 Financial Results and Provides Business Update

Stay Connected